Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Chinese Patent Office
Deloitte
UBS
Cantor Fitzgerald
Accenture
Healthtrust
Farmers Insurance
Fish and Richardson

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VIGABATRIN

« Back to Dashboard

Clinical Trials for Vigabatrin

Trial ID Title Status Sponsor Phase Summary
NCT00373581 Effects of Vigabatrin on Cocaine Self-Administration Terminated Novel Cocaine Pharmacotherapies Phase 2 The objective of this study is to determine if vigabatrin will decrease cocaine self-administration, cardiovascular effects, subjective effects and craving compared to placebo.
NCT00373581 Effects of Vigabatrin on Cocaine Self-Administration Terminated New York State Psychiatric Institute Phase 2 The objective of this study is to determine if vigabatrin will decrease cocaine self-administration, cardiovascular effects, subjective effects and craving compared to placebo.
NCT00441896 A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms Completed Marinus Pharmaceuticals Phase 2 The study is a two period (8-10 days/period), incomplete cross-over in which successive cohorts of 9 subjects are randomized, in a 2:1 ratio, to 1 of 2 sequences, A and B. In each cohort, Sequence A, comprised of 6 subjects, receives ascending doses of ganaxolone during period 1 and ganaxolone (at the maximal dose attained in period 1) and ascending doses of placebo during period 2. Sequence B, comprised of 3 subjects, receives ascending doses of placebo during period 1 and receives the maximum dose of placebo and ascending doses of ganaxolone during period 2. The dosing level in each subsequent cohort will be based upon experience gained from previous cohorts.
NCT00506935 Assessment of GVG for the Treatment of Methamphetamine Dependence Completed University of California, Los Angeles Phase 1 The purpose of this study is to find out if GVG can reduce drug use and determine safety and effects of GVG when used together with methamphetamine. This study involves staying in the hospital for 21 days. Participants will receive either placebo or GVG, and a limited amount if methamphetamine will be injected on some study days. This study will enroll people that use methamphetamine. Participants will be compensated.
NCT00506935 Assessment of GVG for the Treatment of Methamphetamine Dependence Completed National Institute on Drug Abuse (NIDA) Phase 1 The purpose of this study is to find out if GVG can reduce drug use and determine safety and effects of GVG when used together with methamphetamine. This study involves staying in the hospital for 21 days. Participants will receive either placebo or GVG, and a limited amount if methamphetamine will be injected on some study days. This study will enroll people that use methamphetamine. Participants will be compensated.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Vigabatrin

Condition Name

Condition Name for Vigabatrin
Intervention Trials
Cocaine Dependence 5
Infantile Spasms 5
Infantile Spasm 2
Cocaine Addiction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vigabatrin
Intervention Trials
Spasms, Infantile 7
Spasm 7
Cocaine-Related Disorders 6
Seizures 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vigabatrin

Trials by Country

Trials by Country for Vigabatrin
Location Trials
United States 71
Mexico 1
Canada 1
France 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vigabatrin
Location Trials
California 7
Texas 7
Florida 5
New York 5
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vigabatrin

Clinical Trial Phase

Clinical Trial Phase for Vigabatrin
Clinical Trial Phase Trials
Phase 4 4
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vigabatrin
Clinical Trial Phase Trials
Completed 9
Recruiting 5
Terminated 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vigabatrin

Sponsor Name

Sponsor Name for Vigabatrin
Sponsor Trials
Catalyst Pharmaceuticals, Inc. 4
National Institute on Drug Abuse (NIDA) 4
Lundbeck LLC 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vigabatrin
Sponsor Trials
Other 27
Industry 10
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
US Department of Justice
Colorcon
Mallinckrodt
QuintilesIMS
US Army
McKinsey
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.